[Use of dexmedetomidine hydrochloride as a sedative during local therapy for hepatocellular carcinoma].
Nihon Shokakibyo Gakkai Zasshi
; 112(3): 547-54, 2015 Mar.
Article
em Ja
| MEDLINE
| ID: mdl-25759230
ABSTRACT
Sedation using dexmedetomidine hydrochloride (DEX) was administered to patients with hepatocellular carcinoma (HCC) prior to local therapy. Case 1 was a 58-year-old man undergoing radiofrequency ablation in combination with transcatheter arterial chemoembolization for HCC in S3. In accordance with the package insert, the initial loading dose was set at 6 µg/kg/hour. Although a favorable sedative effect was achieved, his blood pressure and pulse rate decreased. Case 2 was a 79-year-old woman undergoing percutaneous ethanol injection therapy for HCC in S6. Half the initial loading dose indicated in the package insert (3 µg/kg/hour) was administered, but the sedative effect was appreciable. No marked blood pressure or pulse rate decreases were observed. We believe that the use of DEX as a sedative agent in local therapy for HCC can be expected to increase. However, the optimal dose setting for DEX requires further examination.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Hepatocelular
/
Dexmedetomidina
/
Hipnóticos e Sedativos
/
Neoplasias Hepáticas
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Ja
Revista:
Nihon Shokakibyo Gakkai Zasshi
Ano de publicação:
2015
Tipo de documento:
Article